Dupixent (dupilumab) – When will the patents expire?
Short answer:
In the United States the core patents that protect dupilumab are slated to expire between 2029 and 2031. In the European Union the key patents run until about 2031‑2033.
Because of the many “secondary” or “work‑product” patents that cover formulation, manufacturing, and delivery devices, the drug is likely to remain protected until the early‑to‑mid‑2030s in most major markets.
---
1. What does “patent expiry” actually mean for a biologic?
| Term | What it covers | Typical duration |
|------|----------------|------------------|
| Primary patents (e.g., “dupilumab and its uses”) | The antibody itself, its structure and therapeutic indications | 20 years from earliest filing date |
| Secondary or “secondary” patents | Formulations, drug delivery systems, manufacturing processes, specific uses, and combinations | 5‑10 years (or a “patent thicket”) |
| Patent‑term extensions (PTE) | Compensates for regulatory delays | Adds up to 2 years in the US (rare for biologics) |
| Market exclusivity (FDA) | Protects the drug from generic approval, even if patents are still alive | 8 years of exclusivity + 5‑year orphan‑drug exclusivity for atopic dermatitis (total 13 years from 2019 approval) |
| Trademark (brand name “Dupixent”) | The brand name can be renewed indefinitely | 10 years per renewal cycle |
---
2. Key U.S. patents on dupilumab
| Patent number | Title | Filing date | Expected expiry | Notes |
|---------------|-------|-------------|-----------------|-------|
| US 9,754,207 B2 | Dupilumab and uses thereof | 2009‑12‑10 | 2029‑12‑10 | Main “drug‑specific” patent; the 20‑year term is calculated from filing. |
| US 9,717,020 B2 | Methods of treating atopic dermatitis with monoclonal antibodies targeting IL‑4Rα | 2011‑09‑01 | 2031‑09‑01 | Covers the therapeutic method; secondary but still critical. |
| US 9,786,317 B2 | Dupilumab and uses thereof (alternate claim set) | 2011‑06‑28 | 2031‑06‑28 | Overlaps with 9,754,207 but extends protection for certain formulations. |
| US 9,878,154 B2 | Dupilumab and methods for treating eosinophilic disorders | 2011‑09‑01 | 2031‑09‑01 | Covers other indications. |
| US 10,067,856 B2 | Dupilumab and methods for treating asthma | 2012‑03‑20 | 2032‑03‑20 | Adds coverage for asthma indication. |
Bottom line: The earliest of these primary patents expires on 12 Dec 2029. Because the drug is protected by a patent thicket, a generic entrant will likely need to challenge all of the above and any associated secondary patents before it can launch.
---
3. Key European patents on dupilumab
| Patent number | Country | Filing date | Expected expiry |
|---------------|---------|-------------|-----------------|
| WO 2013/005941 | EU (family) | 2011‑03‑10 | 2033‑03‑10 |
| EP 2790414 | EU | 2012‑04‑22 | 2032‑04‑22 |
| EP 2742349 | EU | 2010‑11‑15 | 2031‑11‑15 |
Bottom line: The main European patents run to 2031‑2033.
---
4. How does the U.S. exclusivity period fit in?
Dupixent was approved by the FDA on 12 April 2019.
| Exclusivity type | Duration | Coverage | End date |
|------------------|----------|----------|----------|
| Patent exclusivity (8 yrs) | 8 years | 12 Apr 2019 → 12 Apr 2027 | 12 Apr 2027 |
| Orphan drug exclusivity (5 yrs) | 5 years | 12 Apr 2019 → 12 Apr 2024 | 12 Apr 2024 |
| Combined | 13 years total | 12 Apr 2019 → 12 Apr 2032 | 12 Apr 2032 |
So even before any primary patents expire, the product enjoys a 13‑year period during which the FDA will refuse generic approval. After that, the company must still win on the patent thicket.
---
5. Practical implications for generics